| dc.creator | Dinos G.P., Athanassopoulos C.M., Missiri D.A., Giannopoulou P.C., Vlachogiannis I.A., Papadopoulos G.E., Papaioannou D., Kalpaxis D.L. | en |
| dc.date.accessioned | 2023-01-31T07:57:04Z | |
| dc.date.available | 2023-01-31T07:57:04Z | |
| dc.date.issued | 2016 | |
| dc.identifier | 10.3390/antibiotics5020020 | |
| dc.identifier.issn | 20796382 | |
| dc.identifier.uri | http://hdl.handle.net/11615/73370 | |
| dc.description.abstract | Chloramphenicol (CAM) is the D-threo isomer of a small molecule, consisting of a p-nitrobenzene ring connected to a dichloroacetyl tail through a 2-amino-1,3-propanediol moiety. CAM displays a broad-spectrum bacteriostatic activity by specifically inhibiting the bacterial protein synthesis. In certain but important cases, it also exhibits bactericidal activity, namely against the three most common causes of meningitis, Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis. Resistance to CAM has been frequently reported and ascribed to a variety of mechanisms. However, the most important concerns that limit its clinical utility relate to side effects such as neurotoxicity and hematologic disorders. In this review, we present previous and current efforts to synthesize CAM derivatives with improved pharmacological properties. In addition, we highlight potentially broader roles of these derivatives in investigating the plasticity of the ribosomal catalytic center, the main target of CAM. © 2016 by the authors; licensee MDPI, Basel, Switzerland. | en |
| dc.language.iso | en | en |
| dc.source | Antibiotics | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85017880069&doi=10.3390%2fantibiotics5020020&partnerID=40&md5=b2872b7a98ef1ba0c85f13ec440801aa | |
| dc.subject | 1,3 diacetyl chloramphenicol | en |
| dc.subject | 3 acetyl chloramphenicol | en |
| dc.subject | alpha dichloroacetamido alpha methylene para nitroacetophenone | en |
| dc.subject | bromo nicetin | en |
| dc.subject | cetophenicol | en |
| dc.subject | chloramphenicol derivative | en |
| dc.subject | chloramphenicol hemisuccinate | en |
| dc.subject | chloramphenicol palmitate | en |
| dc.subject | chloramphenicol spearmine | en |
| dc.subject | collagenase 3 | en |
| dc.subject | florfenicol | en |
| dc.subject | heterodimer | en |
| dc.subject | homodimer | en |
| dc.subject | lincophenicol | en |
| dc.subject | multidrug and toxin extrusion protein 1 | en |
| dc.subject | nicetin | en |
| dc.subject | sparsophenicol | en |
| dc.subject | tevenel | en |
| dc.subject | thiamphenicol | en |
| dc.subject | unclassified drug | en |
| dc.subject | antibacterial activity | en |
| dc.subject | antibiotic sensitivity | en |
| dc.subject | antineoplastic activity | en |
| dc.subject | bacterial survival | en |
| dc.subject | cell invasion | en |
| dc.subject | chemical modification | en |
| dc.subject | DNA damage | en |
| dc.subject | gene mutation | en |
| dc.subject | immune deficiency | en |
| dc.subject | immune response | en |
| dc.subject | multidrug resistance | en |
| dc.subject | nonhuman | en |
| dc.subject | priority journal | en |
| dc.subject | protein synthesis inhibition | en |
| dc.subject | Review | en |
| dc.subject | MDPI AG | en |
| dc.title | Chloramphenicol derivatives as antibacterial and anticancer agents: Historic problems and current solutions | en |
| dc.type | other | en |